22 results about "Visual acuity loss" patented technology

The present disclosure provides for recombinant AAV therapies for the treatment of vision loss associated with Friedreich's ataxia. These therapies are designed for administration to subjects, such as human subjects, including humans diagnosed with or suffering from Friedreich's ataxia. The disclosed vectors comprise transgenes that encode frataxin protein, such as a FXN trans gene encoding human frataxin protein.

The invention discloses a small vision detection device for eye examination, and particularly relates to the technical field of vision detection devices.The small vision detection device comprises a device bottom plate, a vision detection mechanism is arranged at the top of the device bottom plate and comprises a first moving plate, and the first moving plate is arranged at the top of the device bottom plate; the top of the first moving plate is fixedly connected with a moving mounting plate, and a display screen is mounted on the front side of the moving mounting plate. By arranging the vision detection mechanism and the adjusting mechanism, the comprehensiveness of vision detection is improved, the vision definition is detected, the type and degree of refractive errors such as myopia, hyperopia and astigmatism can be accurately diagnosed through a diopter test, whether a vision problem exists or not is determined, and the vision detection accuracy is improved. Meanwhile, some eye diseases possibly influencing vision can be indirectly found through intraocular pressure testing, retina injury and vision loss caused by too high intraocular pressure can be prevented by monitoring changes of the intraocular pressure, the examination effect is good, and vision detection is more comprehensive.

Systems and methods are provided for improving overall vision in patients suffering from a loss of vision in a portion of the retina (e.g., loss of central vision) by providing symmetric or asymmetric optic with aspheric surface which redirects and / or focuses light incident on the eye at oblique angles onto a peripheral retinal location. The intraocular lens can include a redirection element (e.g., a prism, a diffractive element, or an optical component with a decentered GRIN profile) configured to direct incident light along a deflected optical axis and to focus an image at a location on the peripheral retina. Optical properties of the intraocular lens can be configured to improve or reduce peripheral errors at the location on the peripheral retina. One or more surfaces of the intraocular lens can be a toric surface, a higher order aspheric surface, an aspheric Zernike surface or a Biconic Zernike surface to reduce optical errors in an image produced at a peripheral retinal location by light incident at oblique angles.

Provided herein are dual vector systems for expressing a Protocadherin-15 protein or variant thereof in a subject, wherein the dual vector system comprises a first vector comprising a first coding polynucleotide that encodes an N-terminal portion of the Protocadherin-15 protein or variant thereof; and a second vector comprising a second coding polynucleotide that encodes a C-terminal portion of the Protocadherin-15 protein or variant thereof, wherein the first coding polynucleotide and the second coding polynucleotide that encode the Protocadherin-15 protein or variant thereof do not overlap.

The present disclosure provides a method of treating a human subject having a retinal disease, the method comprising administering to the eye of the subject by intravitreal injection a composition comprising a compound of formula (I) as described herein.

Disclosed is a method of delaying the onset of Stargardt disease symptoms in an asymptomatic Stargardt disease patient. Also disclosed is a method of delaying the onset of vision loss in an asymptomatic Stargardt disease patient. Also disclosed is a method of treating a Stargardt disease patient to delay the onset of vision loss in the Stargardt disease patient, wherein treatment is initiated prior to the patient experiencing vision loss resulting from the Stargardt disease. The methods comprise administering to the patient an effective amount of gildeuretinol acetate.

Certain embodiments disclosed herein include projecting an azimuthal grid into a patient's eye. A computer system projects the azimuthal grid into the patient's eye while taking one or more images of the patient's retina, for example, using SLO. A fixation grid may also be displayed, and the patient is instructed to gaze at a fixation target. The computer system overlays the azimuthal grid onto one or more images to obtain one or more output images. One or more output images are displayed to at least one of the surgeon and / or the patient. The surgeon and / or the patient may examine the output images and use the coordinates of the azimuthal grid to communicate the location of a floating object.

Disclosed herein are methods, devices, and systems for monitoring fluid outflow behavior of an eye of a subject, for example, during ocular surgery. Changes to intraocular pressure can reflect fluid outflow behavior. Fluid outflow behavior can be a critical factor in the successful outcome of a surgery and determining likelihood of post-operative side effects. Large fluctuations in intraocular pressure, ocular hypertension, and hypotony can be associated with vision loss or poor ocular health.

To provide a system that prevents impaired eyesight by following movement of an eye and issuing an alert with respect to a motion that causes impaired eyesight.SOLUTION: A system includes: a spectacle type device; communication means with a smartphone or personal computer; means that follows a motion of an eye; and means that issues an alert with respect to a motion that causes impaired eyesight.SELECTED DRAWING: Figure 1

Disclosed is a method of treating a patient with Geographic Atrophy or with wet Age-related Macular Degeneration or Choroidal Neovascularization. Also disclosed is a method of delaying the progression of vision loss in a patient with Geographic Atrophy or with wet Age-related Macular Degeneration or Choroidal Neovascularization. The methods comprise administering an effective amount of gildeuretinol acetate to the patient.

Systems and methods are provided for improving overall vision in patients suffering from a loss of vision in a portion of the retina (e.g., loss of central vision) by providing a piggyback lens which in combination with the cornea and an existing lens in the patient's eye redirects and / or focuses light incident on the eye at oblique angles onto a peripheral retinal location. The piggyback lens can include a redirection element (e.g., a prism, a diffractive element, or an optical component with a decentered GRIN profile) configured to direct incident light along a deflected optical axis and to focus an image at a location on the peripheral retina. Optical properties of the piggyback lens can be configured to improve or reduce peripheral errors at the location on the peripheral retina. One or more surfaces of the piggyback lens can be a toric surface, a higher order aspheric surface, an aspheric Zernike surface or a Biconic Zernike surface to reduce optical errors in an image produced at a peripheral retinal location by light incident at oblique angles.

Disclosed herein are methods, devices, and systems for monitoring fluid outflow behavior of an eye of a subject, for example, during ocular surgery. Changes to intraocular pressure can reflect fluid outflow behavior. Fluid outflow behavior can be a critical factor in the successful outcome of a surgery and determining likelihood of post-operative side effects. Large fluctuations in intraocular pressure, ocular hypertension, and hypotony can be associated with vision loss or poor ocular health.

Disclosed herein are cells, cellular compositons, methods, and systems for restoring vision loss in a patient suffering from same. In many embodiments, the disclosed cells may be retinal ganglion cells (RGCs) expressing one or more survival-enhancing factors, for example small heat shock protein Bl, HSPB 1, which may be driven by an RGC-specific promoter. In many embodiments, expression of the survival-enchancing factor may allow RGCs transplanted into the patient's retina to more effectively repopulate the RGC population.

For example, the present invention provides compositions and methods for treating and / or preventing at least one disease, disorder, and / or condition associated with vision loss, including age-related macular degeneration. [Solution] A composition is provided comprising vitamin C, vitamin E, zinc, copper, and a potent vitamin B complex, as well as a pharmaceutically acceptable salt of any of the above. The composition is useful, for example, in methods for treating conditions associated with vision loss, including age-related macular degeneration.

Disclosed herein are cells, cellular compositons, methods, and systems for restoring vision loss in a patient suffering from same. In many embodiments, the disclosed cells may be retinal ganglion cells (RGCs) expressing one or more survival-enhancing factors, for example small heat shock protein Bl, HSPB 1, which may be driven by an RGC-specific promoter. In many embodiments, expression of the survival-enchancing factor may allow RGCs transplanted into the patient's retina to more effectively repopulate the RGC population.

The system according to this embodiment aims to provide early detection and countermeasures for vision loss and visual impairment. [Solution] The system according to the embodiment comprises a collection unit, an analysis unit, a detection unit, a notification unit, and a suggestion unit. The collection unit collects visual acuity test data, eye photographs, and lifestyle data. The analysis unit analyzes the data collected by the collection unit to understand the individual's visual state. The detection unit detects abnormalities based on the data analyzed by the analysis unit. The notification unit notifies the abnormalities detected by the detection unit in real time. The suggestion unit proposes preventive measures and corrective measures based on the abnormalities detected by the detection unit.

Systems and methods are provided for improving overall vision in patients suffering from a loss of vision in a portion of the retina (e.g., loss of central vision) by providing symmetric or asymmetric optic with aspheric surface which redirects and / or focuses light incident on the eye at oblique angles onto a peripheral retinal location. The intraocular lens can include a redirection element (e.g., a prism, a diffractive element, or an optical component with a decentered GRIN profile) configured to direct incident light along a deflected optical axis and to focus an image at a location on the peripheral retina. Optical properties of the intraocular lens can be configured to improve or reduce peripheral errors at the location on the peripheral retina. One or more surfaces of the intraocular lens can be a toric surface, a higher order aspheric surface, an aspheric Zernike surface or a Biconic Zernike surface to reduce optical errors in an image produced at a peripheral retinal location by light incident at oblique angles.

The invention relates to the field of medicine, in particular to application of a substance specifically combined with NSE protein or a coding gene thereof to preparation of an ARN diagnosis product or a prognosis product. By detecting the NSE protein or the encoding gene thereof, optic neuropathy caused by acute retinal necrosis can be informed, and doctors can recognize ARN diseases earlier, so that proper medical intervention can be implemented quickly. Therefore, the risk of retinal abscission and visual loss can be remarkably reduced, clinical doctors can be assisted in accurately evaluating the severity of the illness state and predicting the possibility of visual recovery, and individuation and precision of treatment can be promoted. In addition, by avoiding unnecessary medicine use and medical resource waste, economic benefits are brought, and both the patient and the society are benefited.

To provide a device for preventing the lowering of eyesight and asthenopia of a user by using a display device such as a portable terminal.SOLUTION: A device for preventing the lowering of eyesight of the present invention is provided in a display device having a front camera provided on a surface side on which a display screen is present. The device for preventing the lowering of eyesight includes: a congestion state measuring device that measures a congestion state of eyes of a user who views the display screen of the display device; an alert unit that issues a predetermined alert; and an alert instruction determination unit that compares the congestion state measured by the congestion state measuring device with an alert congestion state stored in advance and instructs the alert unit to issue an alert when it is determined that a predetermined condition is satisfied.SELECTED DRAWING: Figure 2

Methods, systems, and devices for improving the assessment of visual function and overcoming limitations of current methods for identifying visual function that a given eye can potentially achieve. Methods for combining multiple eye tests, including visual stimuli and optical measurement components, and their results to identify and quantify causes of vision loss attributable to optical sources such as the lens and cornea as distinct from retinal sources. By identifying potential correctable optical causes of vision loss and overcoming physiological limitations such as the eye's pupil size, the visual benefits of treatment such as cataract or corneal surgery are differentiated from retinal pathologies that require medical intervention. The devices and methods provide metrics that include predictors of visual function and sources of variation, including both optical and neural components, to guide treatment and improve clinical trials.

Disclosed is a method of delaying the onset of Stargardt disease symptoms in an asymptomatic Stargardt disease patient. Also disclosed is a method of delaying the onset of vision loss in an asymptomatic Stargardt disease patient. Also disclosed is a method of treating a Stargardt disease patient to delay the onset of vision loss in the Stargardt disease patient, wherein treatment is initiated prior to the patient experiencing vision loss resulting from the Stargardt disease. The methods comprise administering to the patient an effective amount of gildeuretinol acetate.